Kari alitalo biography of martin garrix

Alitalo discovered vascular growth factors that regulate growth of lymphatic vessels lymphangiogenesis , and characterized the involved receptors and signalling mechanisms. He isolated and characterized the arterial endothelial tyrosine kinase Bmx and endothelial receptor tyrosine kinase Tie1, which together with Tie2 forms the receptor complex for angiopoietins involved regulation of vascular permeability, inflammation, angiogenesis and lymphangiogenesis.

Inhibitors of this pathway from his laboratory are phase 2 clinical trial in age-related macular degeneration and diabetic macular edema. He demonstrated mechanisms of lymphedema, and developed growth factor therapy for lymphedema, which has now undergone a phase 2 clinical trial. His recent findings include the discovery of meningeal lymphatic vessels, a molecular model of angiopoietin-Tie receptor complex at endothelial cell-cell junctions, and characterization of angiopoietin-2 mutations in human lymphedema.

Alitalo is best known for his work on oncogenes and mechanisms of angiogenesis. He discovered lymphangiogenesis its regulation by growth factors, receptors and signaling mechanisms. He has isolated and characterized several tyrosine kinases including the endothelial receptor tyrosine kinase Tie1, which is related to the Tie2 receptor for angiopoietins and implicated in tumor angiogenesis.

Area 21 Martin Garrix Maejor. A.

His laboratory is curerntly studying its function as a coronary vascular growth factor and metabolic regulator in the heart. The inhibitors of these pathways from his laboratory have now entered phase I clinical trials. He is also interested in molecular therapies for lymphedema, which are entering clinical trials. Recent work in his laboratory heve also led to studies of the homeobox transcription factor Prox1 in colon carcinoma stem cells and tumor progression.

Kari Alitalo. University of Helsinki. Research Interests. Membership Type International Member. Election Year